Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Two men are facing federal charges for allegedly participating in a scheme to smuggle contraband from China into the United States via the ports of Los Angeles and Long Beach, officials announced ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide. Topline results from the Phase 2b ...

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

Breast cancer (BC) is one of the most common malignancies and the leading cause of cancer-related mortality in women. Androgen receptor (AR) is frequently expressed in diverse BC subtypes.